<DOC>
	<DOCNO>NCT02851004</DOCNO>
	<brief_summary>This multicenter , open-label Phase Ib/II study exploratively evaluate efficacy safety BBI608 combination pembrolizumab patient metastatic colorectal cancer ( CRC ) respond intolerant standard chemotherapy .</brief_summary>
	<brief_title>Special Combination BBI608 Pembrolizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients personally provide write consent subject study 2 . Age 20 year old day inform consent 3 . [ Phase Ib ] Histologically confirm gastrointestinal cancer [ Phase II ] Histologically confirm colon rectal cancer adenocarcinoma , identification least KRAS codon 12 13 mutation status determine RAS gene test . Confirmation microsatellite instability ( MSI ) status . 4 . [ Phase Ib ] Gastrointestinal cancer respond intolerant standard chemotherapy [ Phase II ] A history treatment one regimens follow standard chemotherapy metastatic CRC , respond tolerated chemotherapy 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 6 . Patients evaluable lesion ( Cohort A Phase II Phase Ib ) measurable lesion ( Cohort B Phase II ) specify RECIST version 1.1 7 . Patients adequate organ function base follow laboratory value measure within 7 day enrollment 8 . Women childbearing potential negative pregnancy test within 7 day enrollment . Both male female patient consent practice appropriate contraception study 4 month discontinuation protocol treatment 9 . Patients expect survival least 3 month Exclusion criteria 1 . Patients receive chemotherapy , moleculartargeted agent and/or palliative radiotherapy within 2 week start protocol treatment recovered toxicity cause previous treatment 2 . Patients underwent general anesthesia , surgery require hospitalization extensive radiotherapy within 4 week start protocol treatment minor surgery implantation central venous access device within two week start protocol treatment 3 . Patients active central nervous system metastases carcinomatous meningitis . 4 . Pregnant lactate woman 5 . Patients unable willing take BBI608 capsule every day 6 . Patients gastrointestinal disease markedly interfere absorption oral formulation judge investigator 7 . Patients active autoimmune disease require systemic treatment within 2 year start protocol treatment . 8 . Patients history sign interstitial lung disease active noninfectious pneumonitis 9 . Patients underwent organ bone marrow transplantation 10 . Patients receive live vaccine within 30 day start protocol treatment 11 . Patients participate another clinical study within 4 week start protocol treatment use use investigational drug device 12 . Patients previously receive immunotherapy drug target PD1 , PDL1 and/or PDL2 BBI608 therapy , take part clinical study pembrolizumab BBI608 13 . Patients uncontrollable complication 14 . Patients history malignancy within 3 year start protocol treatment . 15 . Patients clinically significant Electrocardiogram ( ECG ) abnormalities 16 . Patients history Human Immunodeficiency Virus ( HIV ) 17 . Patients active hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>